skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Liquid biopsy enters the clinic - implementation issues and future challenges

Nature reviews. Clinical oncology, 2021-05, Vol.18 (5), p.297-312 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;Springer Nature Limited 2021. ;ISSN: 1759-4774 ;EISSN: 1759-4782 ;DOI: 10.1038/s41571-020-00457-x ;PMID: 33473219

Full text available

Citations Cited by
  • Title:
    Liquid biopsy enters the clinic - implementation issues and future challenges
  • Author: Ignatiadis, Michail ; Sledge, George W ; Jeffrey, Stefanie S
  • Subjects: Biopsy ; Blood ; Bone marrow ; Cancer ; Cancer cells ; Cancer screening ; Clinical trials ; Deoxyribonucleic acid ; Diagnosis ; DNA ; Genetic aspects ; Integration ; Management ; Medical examination ; Medical screening ; Metastases ; Methods ; Patients ; Peripheral blood ; Solid tumors
  • Is Part Of: Nature reviews. Clinical oncology, 2021-05, Vol.18 (5), p.297-312
  • Description: Historically, studies of disseminated tumour cells in bone marrow and circulating tumour cells in peripheral blood have provided crucial insights into cancer biology and the metastatic process. More recently, advances in the detection and characterization of circulating tumour DNA (ctDNA) have finally enabled the introduction of liquid biopsy assays into clinical practice. The FDA has already approved several single-gene assays and, more recently, multigene assays to detect genetic alterations in plasma cell-free DNA (cfDNA) for use as companion diagnostics matched to specific molecularly targeted therapies for cancer. These approvals mark a tipping point for the widespread use of liquid biopsy in the clinic, and mostly in patients with advanced-stage cancer. The next frontier for the clinical application of liquid biopsy is likely to be the systemic treatment of patients with 'ctDNA relapse', a term we introduce for ctDNA detection prior to imaging-detected relapse after curative-intent therapy for early stage disease. Cancer screening and diagnosis are other potential future applications. In this Perspective, we discuss key issues and gaps in technology, clinical trial methodologies and logistics for the eventual integration of liquid biopsy into the clinical workflow.
  • Publisher: England: Nature Publishing Group
  • Language: English
  • Identifier: ISSN: 1759-4774
    EISSN: 1759-4782
    DOI: 10.1038/s41571-020-00457-x
    PMID: 33473219
  • Source: ProQuest Central
Back to results list
Go to Previous pagePrevious Result  13 NextGo to Next page
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait